|
|
|
||||||||||
at time of writing, Pharmacotherapy Fellow, College of Pharmacy, Ohio State University, Columbus, OH; now, Assistant Professor, Cooperative Pharmacy Program, University of TexasPan American, Edinburg, TX
Professor of Pharmacy and Division Chair, College of Pharmacy; Professor of Pediatrics and Internal Medicine, College of Medicine and Public Health, Ohio State University and Children's Hospital, Columbus, OH
Reprints: Dr. Nahata, College of Pharmacy, Ohio State University, 500 W. 12th Ave., Columbus, OH 43210-1291, fax 614/292-1335
OBJECTIVE: To review the safety and efficacy of selective serotonin-reuptake inhibitors (SSRIs) for the treatment of depression in adults with HIV.
DATA SOURCES: We searched Pre-MEDLINE and MEDLINE (1966May 2004) using terms including generic names of antidepressants and antiretrovirals, depression, HIV, and acquired immunodeficiency syndrome. All English-language articles were included in this review.
DATA SYNTHESIS: SSRIs may be effective and better tolerated than tricyclic antidepressants in HIV-positive adults. SSRIs did not appear to affect CD4+ cell counts.
CONCLUSIONS: Controlled trials comparing SSRIs are lacking; thus, it is difficult to determine whether one SSRI is more efficacious than another. It appears that most SSRIs may be used in HIV-positive adults. If drugdrug interactions are a concern, sertraline, citalopram, and possibly escitalopram may be considered.
Key Words: adults, antiretrovirals, selective serotonin-reuptake inhibitors
Published Online, November 23, 2004. www.theannals.com, DOI 10.1345/aph.1E248